APC anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_APC_021606
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
  • 145-2C11_APC_021606
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100311 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100312 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD3ε antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  2. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  3. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  4. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  5. Wang Q, et al. 2020. Radiat Environ Biophys. 59:89. PubMed
  6. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  7. Pennock N, et al. 2014. Proc Natl Acad Sci U S A. 111:16472. PubMed
  8. Ajina R, et al. 2019. Oncoimmunology. 8:e1577127. PubMed
  9. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  10. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  11. Fujimori S, et al. 2022. Elife. 11:. PubMed
  12. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  13. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  14. Okamoto M, et al. 2014. J Immunol. 192:2770. PubMed
  15. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  16. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  17. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  18. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  19. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  20. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  21. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  22. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  23. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  24. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  25. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  26. Jung BG, et al. 2022. PLoS Pathog. 18:e1010454. PubMed
  27. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  28. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  29. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  30. Gao JL, et al. 2019. JCI Insight. 4:e132140. PubMed
  31. Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed
  32. Wang J, et al. 2018. Front Immunol. 9:371. PubMed
  33. Zhou H, et al. 2022. EMBO Rep. 23:e53475. PubMed
  34. Wan W, et al. 2015. Cardiovasc Res. 106:478. PubMed
  35. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  36. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  37. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  38. Leiva M, et al. 2016. Nat Commun. 7:10222. PubMed
  39. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  40. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  41. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  42. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  43. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  44. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  45. Dong S, et al. 2021. Nature. 591:117. PubMed
  46. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  47. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  48. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  49. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  50. Siggs O, et al. 2015. Proc Natl Acad Sci U S A. 112: E5706 - E5714. PubMed
  51. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  52. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  53. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  54. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  55. Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  56. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  57. Oksenych V, et al. 2021. Biomolecules. 12:. PubMed
  58. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  59. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  60. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  61. Uto T, et al. 2016. Nat Commun. 7: 11273. PubMed
  62. Rovira-Clavé X, et al. 2016. J Leukoc Biol. 99: 143 - 152. PubMed
  63. XS R, et al. 2015. Diabetes. 64 90. PubMed
  64. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  65. Ghandhi SA, et al. 2019. Sci Rep. 9:19434. PubMed
  66. Xia P et al. 2018. Immunity. 48(4):688-701 . PubMed
  67. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  68. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  69. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  70. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  71. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  72. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  73. Liu Y, et al. 2022. Am J Transl Res. 14:6856. PubMed
  74. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  75. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  76. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  77. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  78. Zhang Q, et al. 2022. JCI Insight. 7:. PubMed
  79. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  80. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  81. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  82. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  83. Liang Q, et al. 2020. Front Microbiol. 11:571847. PubMed
  84. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  85. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  86. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  87. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  88. Castañeda–Zegarra S, et al. 2019. Biomolecules. 0.929166667. PubMed
  89. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  90. Omatsu Y, et al. 2022. Nat Commun. 13:2654. PubMed
  91. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  92. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  93. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  94. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  95. Düking T, et al. 2022. Sci Adv. 8:eabo7639. PubMed
  96. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  97. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  98. Koide S, et al. 2022. iScience. 25:103603. PubMed
  99. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  100. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  101. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  102. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  103. Sato Y, et al. 2022. Front Mol Biosci. 9:1040237. PubMed
  104. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  105. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  106. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  107. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  108. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  109. Stephens HM, et al. 2022. Methods Mol Biol. 2478:727. PubMed
  110. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  111. Xu G, et al. 2015. Free Radic Biol Med. 87: 15-25. PubMed
  112. Cruz F, et al. 2016. Stem Cells Trans Med. 5: 488-499. PubMed
  113. Huang X, et al. 2021. Immunity. . PubMed
  114. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  115. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  116. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  117. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  118. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  119. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  120. Yu YR, et al. 2020. STAR Protocols. 11(3):e0150606. PubMed
  121. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  122. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  123. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
RRID
AB_312676 (BioLegend Cat. No. 100311)
AB_312677 (BioLegend Cat. No. 100312)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD3ε

  • Biotin anti-mouse CD3ε

  • FITC anti-mouse CD3ε

  • PE anti-mouse CD3ε

  • PE/Cyanine5 anti-mouse CD3ε

  • Purified anti-mouse CD3ε

  • PE/Cyanine7 anti-mouse CD3ε

  • Alexa Fluor® 488 anti-mouse CD3ε

  • Alexa Fluor® 647 anti-mouse CD3ε

  • PerCP anti-mouse CD3ε

  • PerCP/Cyanine5.5 anti-mouse CD3ε

  • Purified anti-mouse CD3ε (Maxpar® Ready)

  • APC/Cyanine7 anti-mouse CD3ε

  • Pacific Blue™ anti-mouse CD3ε

  • Brilliant Violet 421™ anti-mouse CD3ε

  • Ultra-LEAF™ Purified anti-mouse CD3ε

  • PE/Dazzle™ 594 anti-mouse CD3ε

  • Brilliant Violet 510™ anti-mouse CD3ε

  • Brilliant Violet 605™ anti-mouse CD3ε

  • Brilliant Violet 711™ anti-mouse CD3ε

  • Brilliant Violet 785™ anti-mouse CD3ε

  • APC/Fire™ 750 anti-mouse CD3ε

  • GoInVivo™ Purified anti-mouse CD3ε

  • Spark YG™ 593 anti-mouse CD3

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account